Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Avatud

SektorTervishoid

2.77 -0.72

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.79

Max

2.89

Põhinäitajad
By Trading Economics
Sissetulek	1.2M -31M
Müük	-70K 1.3M
Aktsiakasum	-0.26
Kasumimarginaal	-2,402.848
Töötajad	161
EBITDA	14M -28M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+79.14% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	10. aug 2026

Turustatistika
By TradingEconomics
Turukapital	108M 361M
Eelmine avamishind	3.49
Eelmine sulgemishind	2.77

Uudiste sentiment

By Acuity

50%

145 / 340 Pingereas Healthcare

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

20. juuli 2026, 18:26 UTC

Fate Therapeutics Inc. shares are effectively unchanged as trading remains flat. The stock has seen strong performance over the past month, nearing its recent highs.

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

79.14% tõus

12 kuu keskmine prognoos

Keskmine 4.98 USD 79.14%

Kõrge 8 USD

Madal 2.2 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

145 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.